A steep rise in the costs of cancer drugs is prompting more oncologists to call for increased scrutiny of the efficacy and value of therapeutics amid what they call rising inequities as health systems struggle to pay for them. Global spending on oncology drugs is expected to reach US$409 billion by 2028, up from $223 billion last year, according to the IQVIA Institute for Human Data Science (Durham, NC, USA).